IntraBio is on a roll with its expansion plans for chemically altered amino acid, Aqneursa. | IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a ...
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the ...
First and only approved treatment indicated for Ataxia-Telangiectasia (A-T) in the United States or anywhere in the world Second FDA-approved indication for AQNEURSA, following previous approval for ...
Every year, the Race for Matt and Grace at Rhode Island College raises hundreds of thousands of dollars to support the Friedreich’s Ataxia Research Alliance.
Add Yahoo as a preferred source to see more of our stories on Google. EAST PROVIDENCE, R.I. (WPRI) — Every year, the Race for Matt and Grace raises hundreds of thousands of dollars to support the ...
Cells can switch off genes by tightly packaging DNA around proteins called histones. However, scientists at St. Jude Children's Research Hospital have discovered that under certain conditions, this ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The startup, backed by a Houston ...
Virtualitics has appointed Kristy Friedrichs as chief operating officer as the artificial intelligence company expands operations to support national security and mission-focused customers. What Will ...
CHICAGO — The modified amino acid levacetylleucine (Aqneursa) significantly improved neurologic symptoms and was well tolerated in patients with ataxia-telangiectasia, a rare genetic disorder that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results